Resources
BOSTON, April 8, 2021 /PRNewswire/ — OM1, a real-world outcomes and technology company, today announced a strategic collaboration with the American Academy of Dermatology (AAD) connecting the Academy’s DataDerm™ clinical data registry to OM1’s real-world data and evidence platforms. The AAD estimates that 1 in 4 Americans (more than 85 million) see a physician for[…]
M.D. Alert Published: March 5, 2021 Read the Full Commentary >> (Reuters Health) – Women have better screening outcomes with digital breast tomosynthesis, but a new study suggests that Black women have less access to this imaging modality. Researchers examined data on 385,503 women screened at one of 63 U.S. breast imaging facilities between 2015[…]
Journal of the American College of Radiology Published: February 16, 2021 Read the Full Manuscript >> Abstract Purpose Digital breast tomosynthesis (DBT) in conjunction with digital mammography (DM) is becoming the preferred imaging modality for breast cancer screening compared with DM alone, on the basis of improved recall rates (RR) and cancer detection rates (CDRs).[…]
BOSTON, Feb. 18, 2021 /PRNewswire/ — OM1, a leading real-world data (RWD), health outcomes and technology company, today announced the publication of clinical trial results in JAMA Network Open demonstrating its tool, OM1™ Joint Insights, positively impacts decision quality, shared decision making, patient experience, and functional outcomes in adults with knee osteoarthritis (OA). In the U.S., more than 30 million adults[…]
BOSTON, Jan. 28, 2021 /PRNewswire/ — OM1, a leading real-world data (RWD), outcomes and technology company with a focus on chronic diseases, today announced the launch of an expanded Heart Failure registry. Heart Failure (HF) is considered a growing healthcare epidemic and is associated with significant mortality, morbidity and resource utilization. In the United States, HF is estimated to[…]
